Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Not wanted at thirty-five

J S Cameron

    Lancet (London, England)
    |May 19, 1979
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Familial juvenile hyperuricaemic nephropathy is not such a rare genetic metabolic purine disease in Britain.

    Nucleosides, nucleotides & nucleic acids·2006
    Same author

    The discovery of diabetic nephropathy: from small print to centre stage.

    Journal of nephrology·2006
    Same author

    Familial juvenile hyperuricaemic nephropathy.

    QJM : monthly journal of the Association of Physicians·2004
    Same author

    Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease.

    QJM : monthly journal of the Association of Physicians·2002
    Same author

    Characteristics and outcome of membranous nephropathy in older patients.

    International urology and nephrology·2002
    Same author

    The continued care of children with renal disease into adult life.

    Pediatric nephrology (Berlin, Germany)·2001
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    Same journal

    Dual mobility total hip replacement in fractures: stability promotes patient confidence.

    Lancet (London, England)·2026
    Same journal

    Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

    Lancet (London, England)·2026
    See all related articles